« Return to News | Clinical Intelligence

Teva, Biogen reveal positive results for MS drugs

Wednesday, April 13, 2011 12:49 PM

Teva and Biogen Idec have presented late-stage data on their respective oral offerings for the treatment of multiple sclerosis (MS), according to Pharma Times.

Laquinimod, made by Teva who partnered with Active Biotech, met the endpoint in the late-stage 1106-patient ALLEGRO trial, demonstrating a 23% reduction in annual relapse rates (AAR) compared to placebo. The study also showed that patients had a 36% reduction in any progression of disability and a 33% decrease in brain atrophy, compared to placebo. Elevated liver enzymes, relative to placebo, were present in some patients, but these increases did not lead to liver problems.

Teva and Active Biotech plan to file for regulatory approval of laquinimod once results from the phase III BRAVO trial are released.

Biogen presented positive results from DEFINE, the first of two phase III trials evaluating BG-12 (dimethyl fumarate) as an oral monotherapy in people with relapsing-remitting MS. Results showed that 240 mg of BG-12, administered either twice or three times a day, met the primary study endpoint, demonstrating a reduction in patients who relapsed at two years compared with placebo. Additional analyses of DEFINE are ongoing.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.